NCT03382977
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03382977
Title Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors VBI Vaccines Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of California, Irvine Irvine California 92868 United States Details
University of California, San Diego La Jolla California 92093 United States Details
University of California, Los Angeles Neuro-Oncology Program Los Angeles California 90095 United States Details
Stanford Stanford California 94305 United States Details
Miami Cancer Institute Miami Florida 33176 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
The Valley Hospital - Neurosurgeons of New Jersey Ridgewood New Jersey 07450 United States Details
The Neurological Institute of New York Columbia University Medical Center New York New York 10032 United States Details
Vanderbilt University Medical Center Nashville Tennessee 37232 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Providence - Swedish Medical Center Seattle Washington 98122 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field